Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group (Q33385371)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group
scientific article

    Statements

    Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group (English)
    Dirk Winkler
    Andreas Bühler
    Richard F Schlenk
    Silja Groner
    Raymonde Busch
    Manfred Hensel
    Ulrich Dührsen
    Jürgen Finke
    Peter Dreger
    Ulrich Jäger
    Eva Lengfelder
    Ulrike Söling
    Rudolf Schlag
    Michael Kneba
    German Chronic Lymphocytic Leukemia Study Group
    3994-4001

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit